•Belite Bio begins rolling NDA submission of oral tinlarebant for Stargardt •Nutritional supplementation is redefining eye health management •Maternal diabetes exposure increases severe ROP risk•Merck kicks off phase 2b/3 trial on tri-specific antibody for wet AMD•Retina Summit 2026: OD updates for AMD management and imaging•Belite Bio begins rolling NDA submission of oral tinlarebant for Stargardt •Nutritional supplementation is redefining eye health management •Maternal diabetes exposure increases severe ROP risk•Merck kicks off phase 2b/3 trial on tri-specific antibody for wet AMD•Retina Summit 2026: OD updates for AMD management and imaging
HEADLINES
FEATURED
Topline data on OCS-01 from DIAMOND program expected in June 2026 with the goal of supporting an NDA submission in Q4 2026.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
